Mia Salans1, Michelle D Tibbs1, Minh-Phuong Huynh-Le1, Anthony Yip1, Kathryn Tringale2, Roshan Karunamuni1, Ronghui Xu3, Anny Reyes4, Anna Christina Macari4, Tonya Pan-Weisz4, Carrie R McDonald5, Jona A Hattangadi-Gluth6. 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Mathematics, University of California San Diego, San Diego, California. 4. Department of Psychiatry, University of California San Diego, San Diego, California. 5. Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California; Department of Psychiatry, University of California San Diego, San Diego, California. 6. Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California. Electronic address: jhattangadi@health.ucsd.edu.
Abstract
PURPOSE: We conducted the first prospective longitudinal study examining the independent association between patient-reported health-related quality of life (hrQoL) (physical, social/family, emotional, functional, and brain cancer-specific) and neurocognitive function (NCF), while controlling for mood symptoms in patients with primary brain tumors. METHODS AND MATERIALS: Patients with primary brain tumors (n = 59) receiving brain radiation therapy underwent hrQOL (Functional Assessment of Cancer Therapy-Brain), mood (Beck Depression and Anxiety Inventories), and neurocognitive evaluation at baseline and 3, 6, and 12 months postradiation therapy in a prospective clinical trial. Neurocognitive assessments measured attention/processing speed, memory, and executive function, including the Delis-Kaplan Executive Function System Verbal Fluency, Hopkins Verbal Learning Test Revised (HVLT-R), and Brief Visuospatial Memory Test. Subjects underwent neurocognitive, mood, and hrQoL assessments in the same testing session. Multivariable linear mixed-effects models assessed associations between hrQOL and NCF over time, controlling for patient, tumor, and treatment characteristics as well as timepoint-specific patient-reported mood (ie, anxiety and depression symptoms). P values were adjusted for multiple comparisons. RESULTS: Higher physical hrQoL was associated with better verbal memory (HVLT-R Total Recall, P = .047), and higher functional hrQoL was associated with better executive function (Delis-Kaplan Executive Function System Verbal Fluency Switching Total, P = .009) and verbal memory (HVLT-R Delayed Recall, P = .006). Higher brain tumor-specific hrQoL was associated with better verbal and nonverbal memory (HVLT-R Total, P = .004 and Delayed Recall, P = .030; Brief Visuospatial Memory Test Total, P = .049 and Delayed Recall, P = .049). There was no association between social/family or emotional hrQoL and NCF after controlling for mood. CONCLUSIONS: Higher physical, functional, and brain tumor-specific hrQoL were associated with better executive function and memory among patients with primary brain tumors. Physical and functional impairments are correlated with cognitive performance. Interventions to maximize quality of life after treatment may influence neurocognition and vice versa.
PURPOSE: We conducted the first prospective longitudinal study examining the independent association between patient-reported health-related quality of life (hrQoL) (physical, social/family, emotional, functional, and brain cancer-specific) and neurocognitive function (NCF), while controlling for mood symptoms in patients with primary brain tumors. METHODS AND MATERIALS: Patients with primary brain tumors (n = 59) receiving brain radiation therapy underwent hrQOL (Functional Assessment of Cancer Therapy-Brain), mood (Beck Depression and Anxiety Inventories), and neurocognitive evaluation at baseline and 3, 6, and 12 months postradiation therapy in a prospective clinical trial. Neurocognitive assessments measured attention/processing speed, memory, and executive function, including the Delis-Kaplan Executive Function System Verbal Fluency, Hopkins Verbal Learning Test Revised (HVLT-R), and Brief Visuospatial Memory Test. Subjects underwent neurocognitive, mood, and hrQoL assessments in the same testing session. Multivariable linear mixed-effects models assessed associations between hrQOL and NCF over time, controlling for patient, tumor, and treatment characteristics as well as timepoint-specific patient-reported mood (ie, anxiety and depression symptoms). P values were adjusted for multiple comparisons. RESULTS: Higher physical hrQoL was associated with better verbal memory (HVLT-R Total Recall, P = .047), and higher functional hrQoL was associated with better executive function (Delis-Kaplan Executive Function System Verbal Fluency Switching Total, P = .009) and verbal memory (HVLT-R Delayed Recall, P = .006). Higher brain tumor-specific hrQoL was associated with better verbal and nonverbal memory (HVLT-R Total, P = .004 and Delayed Recall, P = .030; Brief Visuospatial Memory Test Total, P = .049 and Delayed Recall, P = .049). There was no association between social/family or emotional hrQoL and NCF after controlling for mood. CONCLUSIONS: Higher physical, functional, and brain tumor-specific hrQoL were associated with better executive function and memory among patients with primary brain tumors. Physical and functional impairments are correlated with cognitive performance. Interventions to maximize quality of life after treatment may influence neurocognition and vice versa.
Authors: Elizabeth L Whitlock; L Grisell Diaz-Ramirez; M Maria Glymour; W John Boscardin; Kenneth E Covinsky; Alexander K Smith Journal: JAMA Intern Med Date: 2017-08-01 Impact factor: 21.873
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Kathleen Ford; Maryfran Sowers; Teresa E Seeman; Gail A Greendale; Barbara Sternfeld; Susan A Everson-Rose Journal: Gerontology Date: 2009-10-10 Impact factor: 5.140
Authors: Lin Lin; Hui-Hsun Chiang; Alvina A Acquaye; Elizabeth Vera-Bolanos; Mark R Gilbert; Terri S Armstrong Journal: Cancer Date: 2013-05-09 Impact factor: 6.860
Authors: Paul D Brown; Vinai Gondi; Stephanie Pugh; Wolfgang A Tome; Jeffrey S Wefel; Terri S Armstrong; Joseph A Bovi; Cliff Robinson; Andre Konski; Deepak Khuntia; David Grosshans; Tammie L S Benzinger; Deborah Bruner; Mark R Gilbert; David Roberge; Vijayananda Kundapur; Kiran Devisetty; Sunjay Shah; Kenneth Usuki; Bethany Marie Anderson; Baldassarre Stea; Harold Yoon; Jing Li; Nadia N Laack; Tim J Kruser; Steven J Chmura; Wenyin Shi; Snehal Deshmukh; Minesh P Mehta; Lisa A Kachnic Journal: J Clin Oncol Date: 2020-02-14 Impact factor: 50.717
Authors: Ashlee R Loughan; Morgan Reid; Kelcie D Willis; Alexandria Davies; Rachel L Boutté; Sarah Barrett; Karen Lo Journal: J Neurooncol Date: 2022-04-08 Impact factor: 4.130